Visual Paradigm Online Free Edition

Myocarditis (AESI) & COVID-19 Vaccine Decision Guide

SAEFVIC

Melbourne VACCINE EDUCATION Centre

Referrals

Myocarditis report to SAEFVIC

Specialist Immunisation Service
(+- Cardiology) referral:
- ***Recommended*** for Brighton 1-3
- ***Optional*** for Brighton 4
- ***Not required*** for Brighton 5 unless significant concerns

Evaluation and Classification

Gather investigations / information

Abnormal ECG / Echo / Troponin / CXR OR Cardiac MRI

Investigations not available or not done

Normal investigations (ECG / Echo / CXR / Troponin)

Brighton Level 1-3

If myocarditis confirmed

Consider cardiac MRI (MBS item 63399) to aid in diagnosis

Brighton Level 4

Brighton Level 5

Next Dose Decision (Dose 2 or Dose 3 / Booster)

> 60 yo → Proceed with non-mRNA vaccine (AZ / NX)

25-59 yo → Consider non-mRNA vaccine (NX)

6 mo-24 yo → Caution required. Only consider further vaccine after individual risk versus benefit discussion. May consider non-mRNA vaccine (NX) if >12yo.

Female 5-59 yo / Male 25-59 yo → Proceed with next dose of same COVID-19 vaccine

Male 6 mo-24 yo → Consider non-mRNA vaccine (NX) if >12yo, or can consider mRNA vaccine after discussion with patient

All age groups → Proceed with eligible vaccine

Only proceed with further vaccination at a minimum of 8 weeks from initial symptom onset, AND after symptoms have completely resolved

Brighton Collaboration Criteria:
Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N, et al. Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499-511.

Updated 5/6/22

AZ = AstraZeneca* mRNA = Spikevax (Moderna), Comirnaty (Pfizer) NX = Nuvaxovid (Novavax)*
*not currently licensed for <18yo

Visual Paradigm Online Free Edition